Marathon Trading Investment Management LLC Takes $267,000 Position in Hims & Hers Health, Inc. $HIMS

Marathon Trading Investment Management LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,350 shares of the company’s stock, valued at approximately $267,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of HIMS. Quaker Wealth Management LLC purchased a new position in Hims & Hers Health during the 2nd quarter worth $29,000. Bessemer Group Inc. raised its holdings in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the first quarter worth about $30,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Hims & Hers Health during the first quarter worth about $41,000. Finally, Larson Financial Group LLC grew its holdings in shares of Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after buying an additional 458 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $41.04 on Friday. The firm’s fifty day simple moving average is $51.28 and its 200-day simple moving average is $50.83. The company has a quick ratio of 4.46, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The stock has a market cap of $9.28 billion, a PE ratio of 76.00, a price-to-earnings-growth ratio of 8.17 and a beta of 2.20. Hims & Hers Health, Inc. has a fifty-two week low of $19.15 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same period in the prior year, the firm posted $0.32 EPS. The firm’s quarterly revenue was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,592 shares of the business’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $57.13, for a total transaction of $662,250.96. Following the sale, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $4,012,354.16. The trade was a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Irene Becklund sold 8,410 shares of the firm’s stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $424,705.00. Following the completion of the transaction, the insider owned 1,418 shares of the company’s stock, valued at approximately $71,609. This represents a 85.57% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 712,271 shares of company stock worth $37,631,985. 13.71% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HIMS. Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, UBS Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $45.27.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.